Literature DB >> 6480016

Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results.

P Crome, R Gain, R Ghurye, R J Flanagan.   

Abstract

The plasma elimination half-life of dextropropoxyphene and its metabolite nordextropropoxyphene was investigated in seven elderly hospital patients after the administration of both single and multiple doses of Distalgesic. The mean elimination half-life of dextropropoxyphene after multiple dosing was 35.7 h (range 24.0-50.6 h) and the mean half-life of nordextropropoxyphene was 53.3 h (range 25.1-76.3 h). The half-lives of both dextropropoxyphene and nordextropropoxyphene are much longer than those reported by other investigators in younger subjects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6480016     DOI: 10.1177/096032718400300105

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  6 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage.

Authors:  R J Flanagan; A Johnston; A S White; P Crome
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

3.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 4.  Dextropropoxyphene: safety and efficacy in older patients.

Authors:  David J Goldstein; Dennis C Turk
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Pharmacological aspects of successful long-term analgesia.

Authors:  Robert Raffa
Journal:  Clin Rheumatol       Date:  2006-06-02       Impact factor: 2.980

6.  [Sustained-release dextropropoxyphene.].

Authors:  K Kurz-Müller; M Zenz
Journal:  Schmerz       Date:  1991-12       Impact factor: 1.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.